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Abstract: p63 protein is widely used to identify myoepithelial cells in breast disease. There have been no compara-
tive studies of the p63 antibodies which detect different isoforms. In this study, we examine the expression profiles 
of p63 protein in benign proliferative diseases and malignant tumors of the breast using pan-p63 and p40 antibod-
ies, and analyze their diagnostic utility and clinical implications. We selected 32 adenoses, 34 intraductal papil-
lomas, 31 ductal carcinoma in situ (DCIS), 257 invasive ductal carcinoma (IDC), and 36 metaplastic carcinomas, 
and created tissue microarray blocks from them. Immunohistochemical assays for p63 protein were performed on 
these samples. We investigated the expression patterns of the pan-p63 (TP63, 4A4, Dako, 1:700), p40 antibody 
[5-17, CalBiochem/EMD Biosciences, 1:2000, p40 (CB)], and p40 antibody [polyclonal, Diagnostic BioSystems, 
1:100, p40 (DB)] in various forms of breast disease. We determined that p63 and p40 (DB) expression in myoepi-
thelial cells was broadly similar and showed cognate clinicopathologic features, unlike p40 (CB). p40 (CB) was more 
sensitive (99.0%) but less specific (85.8%), and p63 was less sensitive (93.8%) in adenosis, IP, and DCIS. In IDCs, 
p63 and p40 (DB) had similar expression in cancer cells; p40 (CB) expression, however, was statistically different. 
In metaplastic carcinomas, both p63 and p40 (DB) had distinct expression profiles, according to their histologic 
subtypes. We conclude that p40 antibodies as well as pan-p63 antibody are specific and sensitive myoepithelial 
cell markers. Interpretation of p40 positivity in cancer cells, however, should be considered carefully, due to their 
relatively lower specificity.
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Introduction
Immunohistochemical analysis is one of the 
most commonly used methods of pathologic 
diagnosis in a broad spectrum of breast dis-
eases. For detecting individually specified cell 
types on immunohistochemical analysis, p63 is 
often used as a sensitive marker to identify 
myoepithelial cells [1, 2]. Particularly, p63 with 
nuclear activity is believed to be more specific 
and sensitive than other myoepithelial cell 
markers such as CD10, SHHCH, and calponin, 
which show cytoplasmic positivity [2]. As p63 
can be used to discriminate between invasive 
ductal carcinoma and sclerosing adenosis or to 
identify myoepithelial cells in papillary neo-
plasm, p63 is helpful in diagnosing metaplastic 
carcinoma of the breast, revealing nuclear posi-
tive over 90% of metaplastic carcinoma cases 
[3]. 
p63 exists in several isoforms; we studied 
TAp63 and ΔNp63 (p40), which have different 
N-terminal domains, such as transactivation 
domain (TA domain) and transcriptionally inac-
tive ΔN domain, respectively [4]. In immunohis-
tochemical analysis of p63, 4A4 antibody, 
which could detect both of TAp63 and ΔNp63 
isoforms, was previously the most widely used 
pan-p63 marker in pathological diagnosis. 
Lately, however, it is being replaced by the p40 
antibody, which can selectively detect ΔNp63 
isoforms and has only recently become avail-
able [5]. Some recent studies for p40 utility in 
lung cancer diagnosis reported that the p40 
antibody was more specific than p63 in distin-
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guishing pulmonary squamous cell carcinoma 
from adenocarcinoma [6, 7]. However, the 
application of p40 antibodies for diverse breast 
tumors remains somewhat ambiguous. 
In this study, we explored the expression pro-
files of p40 and p63 in an array of breast dis-
eases, and found that these may be valuable 
myoepithelial markers for detecting myoepithe-




We selected surgical tissue paraffin blocks 
from the pathology archives of Severance hos-
pital, using 32 cases of adenosis, 34 cases of 
intraductal papilloma, 31 cases of ductal carci-
noma in situ (DCIS), 257 cases of invasive duc-
tal carcinoma (IDC), and 36 cases of metaplas-
tic carcinoma. 
Breast cancer cases which had been surgically 
resected in Severance hospital were diagnosed 
as IDC, not specific type (NST) (from January 
2006 to December 2006) and metaplastic car-
cinoma (from January 2005 and December 
2011). Patients who received pre-operation 
neoadjuvant chemotherapy or hormonal treat-
ment were excluded. We retrieved various clini-
copathologic factors, such as patient age, sur-
vival, tumor recurrence, tumor stage, lymph 
node metastasis, histologic grade, expression 
status of estrogen receptor (ER)/progesterone 
receptor (PR)/HER-2, and Ki-67 labeling index 
(LI). The histological grade of IDC and meta-
plastic carcinoma were assessed using the 
Nottingham grading system [8]. We subdivided 
metaplastic carcinomas into several groups, 
according to the histologically dominant fea-
tures: squamous cell differentiation, spindle 
cell metaplasia, rhabdoid differentiation, and 
matrix-producing. Pathologic parameters such 
as ER, PR, and HER-2 status were obtained 
from patients’ pathologic reports. A cut-off 
value of 1% or more positively stained nuclei 
was used to define ER and PR positivity [9]. 
HER-2 staining was analyzed, according to the 
American Society of Clinical Oncology (ASCO)/
College of American Pathologists (CAP) guide-
lines, using the following categories: 0 = no 
immunostaining; 1+ = weak incomplete mem-
branous staining, less than 10% of tumor cells; 
2+ = complete membranous staining, either 
uniform or weak in at least 10% of tumor cells; 
and 3+ = uniform intense membranous staining 
in at least 30% of tumor cells [10]. HER-2 immu-
nostaining was considered positive when 
strong (3+) membranous staining was observed, 
whereas cases with 0 to 1+ were regarded as 
negative. The cases showing 2+ HER-2 expres-
sion were evaluated for HER-2 amplification by 
fluorescent in situ hybridization (FISH).
This study was approved by the Institutional 
Review Board of Yonsei University Severance 
Hospital. The authors, including a breast 
pathologist (Koo JS), retrospectively reviewed 
the histology of all cases using H&E stained 
slides.
Tumor phenotype classification
In this study, we classified breast cancer phe-
notypes according to immunohistochemistry 
results for ER, PR, HER-2 and Ki-67 and FISH 
results for HER-2 as follows [11]: luminal A type: 
ER or/and PR positive and HER-2 negative and 
Ki-67 LI < 14%, Luminal B type: (HER-2 nega-
tive) ER or/and PR positive and HER-2 negative 
and Ki-67 LI ≥ 14%, (HER-2 positive) ER or/and 
PR positive and HER-2 overexpressed or/and 
amplified, HER-2 overexpression type: ER and 
PR negative and HER-2 overexpressed or/and 
amplified, TNBC type: ER, PR, and HER-2 
negative. 
Tissue microarray
We reviewed H&E-stained slides and retrospec-
tively selected formalin-fixed paraffin-embed-
ded (FFPE) tumor tissue samples. We choose 
the most representative tumor areas, and the 
corresponding FFPE sample cores that were 
removed were as small as 3 mm. We made two 
cores for each case. These separate tissue 
cores were assembled in an array fashion. 
Immunohistochemistry 
Immunohistochemical staining was performed 
by Ventana Discovery XT automated stainer 
(Ventana Medical System, Tucson, AZ, USA) 
after antigen retrieval using CC1 buffer (Cell 
Conditioning 1; tris-base buffer PH 8.0, Ventana 
Medical System). Antibodies used for detecting 
p63 protein were as follows: p40 antibody 
[5-17, CalBiochem/EMD Biosciences, 1:2000, 
p40 in breast disease
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p40 (CB)], p40 antibody [polyclonal, Diagnostic 
BioSystems, 1:100, p40 (DB)], and p63 (TP63, 
4A4, Dako, 1:700). The proper positive and 
negative control samples were included in the 
TMA blocks, and the immunohistochemistry 
was performed under the same conditions for 
all samples. We assess p63 or p40 positivity 
when nuclear staining was identified in the 
myoepithelial cells or the cancer cells.
Interpretation of immunohistochemical stain-
ing
We made a detailed assessment for the expres-
sion of the antibodies listed above for p63 pro-
tein in the various breast diseases. We evalu-
ated each of the expression profiles in the myo-
epithelial cells of adenosis, intraductal papillo-
ma, and DCIS, and the cancer cells of IDC and 
metaplastic carcinoma. Only nuclear staining 
was interpreted as positive for p63 and p40 
expression in the myoepithelial cells of adeno-
ses, intraductal papillomas, and DCIS. In addi-
tion, 5% was used as the positive cut off of p63 
or p40 positivity in IDC and metaplastic carci-
noma [3].
Sensitivity, specificity, Positive Predictive Palue 
(PPV), Negative Predictive Value (NPV), and 
accuracy
We calculated the values of sensitivity, specific-
ity, Positive Predictive Value (PPV), Negative 
Predictive Value (NPV), and accuracy, in analyz-
ing p40 and p63 expressions in the myoepithe-
lial cells and luminal ductal cells, using the fol-
lowing definition: sensitivity = 100 × true posi-
tive/(true positive + false negative); specificity 
= 100 × true negative/(true negative + false 
positive); PPV = 100 × true positive/(true posi-
tive + false positive); NPV = 100 × true nega-
tive/(true negative + false negative); and accu-
racy = 100 × (true positive + true negative)/
(true positive + true negative + false positive + 
false negative). Table 1 presents the definitions 
of true positive, false positive, true negative, 
false negative for p63 and p40 immunostain-
ing. These measurement methods were 
applied to adenosis, intraductal papilloma, 
and DCIS. 
Statistical analysis
Data were processed using SPSS for 
Windows, version 12.0 (SPSS Inc., Chicago, 
IL, USA). Student’s t and Fisher’s exact 
Table 1. Definition of True Positive, False Positive, True 
Negative, False Negative in p63 and p40 Immunos-
taining
Cell compartment Myoepithelial cell Luminal ductal cell
p63 or p40 positive True positive False positive
p63 or p40 negative False negative True negative
tests were used to examine differences in con-
tinuous and categorical variables, respectively. 
Two-tailed Mann-Whitney tests were used for 
comparing p63, p40 (DB), and p40 (CB) immu-
nohistochemical expression profiles in IDCs 
and metaplastic carcinomas. P-values of less 
than 0.05 were used to determine signifi- 
cance.
Results
Immunohistochemical analysis of p63, p40 
(DB), and p40 (CB) for breast disease accord-
ing to the composed cell compartment
We collected and reviewed cases diagnosed as 
adenosis, intraductal papilloma, DCIS, IDC, and 
metaplastic carcinoma in the breast and made 
tissue microarray blocks. Then, we performed 
immunohistochemical analysis of the various 
breast diseases, using p63 and p40 primary 
antibodies, for identifying and comparing imm- 
unohistochemical profiles (Table 2). 
First, we verified the expression patterns of dif-
ferent myoepithelial markers in proliferative 
lesions (adenosis) and benign tumors (intra-
ductal papilloma). In cases of adenosis, the 
markers p63, p40 (DB), and p40 (CB) were all 
expressed in the myoepithelial cells, not in the 
luminal ductal cells (Figure 1, top panels). In 
intraductal papillomas, luminal ductal cells did 
not express p63 and p40 (DB), however, most 
cases except three expressed these two mark-
ers in the myoepithelial cells (Figure 1, middle 
panels). The myoepithelial cells in two out of 
these three cases did not show activity for p63 
or p40 (DB). On the other hand, p40 (CB) 
showed positive activity in the myoepithelial 
cells of every intraductal papilloma, and even in 
the luminal ductal cells of one intraductal 
papilloma. 
In DCISs, most cases expressed p63 (28 cases, 
90.3%) and p40 (DB) (30 cases, 96.8%) in the 
surrounding myoepithelial cells (Figure 1, bot-
tom panels). On the other hand, p40 (CB) posi-
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tivity (9 cases, 29.0%) was more frequently 
observed than p63 and p40 (DB) in the neo-
plastic cells of DCISs. One DCIS did not show 
any activity for p63, p40 (DB), or p40 (CB) myo-
epithelial markers on either myoepithelial cells 
or neoplastic cells.
Next, we investigated p63, p40 (DB), and p40 
(CB) expression profiles in the malignant 
tumors: IDC and metaplastic carcinoma. In the 
case of malignant tumors, we examined the 
expression patterns of myoepithelial markers 
on the cancer cells, not on the myoepithelial 
cells, because, by definition, the myoepithelial 
cells are lost in malignant tumors. Cancer cells 
expressed p63 in seven cases (2.7%), p40 (DB) 
in five cases (1.9%), and p40 (CB) in 30 cases 
(11.7%), respectively, out of 257 invasive ductal 
carcinomas (Figure 2, top panels). Metaplastic 
carcinomas more frequently showed nuclear 
activity in myoepithelial markers in cancer cells: 
p63 in nine cases (25.0%); p40 (DB) in ten 
Table 2. Immunohistochemical Profiles of p63, p40 (DB), and p40 (CB) in Each Cell Component Ac-
cording to the Breast Disease
Diagnosis Adenosisn = 32 (%)
Intraductal papilloma
n = 34 (%)
DCIS 
n = 31 (%)
IDC  
n = 257 (%)
Metaplastic carci-




















    Positive 32 (100.0) 0 (0.0) 31 (91.2) 0 (0.0) 28 (90.3) 1 (3.2) 7 (2.7) 9 (25.0)
    Negative 0 (0.0) 32 (100.0) 3 (8.8) 34 (100.0) 3 (9.7) 30 (96.8) 250 (97.3) 27 (75.0)
P40 (DB)
    Positive 32 (100.0) 0 (0.0) 31 (91.2) 0 (0.0) 29 (93.5) 1 (3.2) 5 (1.9) 10 (27.8)
    Negative 0 (0.0) 32 (100.0) 3 (8.8) 34 (100.0) 2 (6.5) 30 (96.8) 252 (98.1) 26 (72.2)
P40 (CB)
    Positive 32 (100.0) 0 (0.0) 34 (100.0) 1 (2.9) 30 (96.8) 9 (29.0) 30 (11.7) 26 (72.2)
    Negative 0 (0.0) 32 (100.0) 0 (0.0) 33 (97.1) 1 (3.2) 22 (71.0) 227 (88.3) 10 (27.8)
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
Figure 1. Immunohistochemical expression of p63, p40 (DB), and p40 (CB) in adenosis, intraductal papilloma 
and ductal carcinoma in situ. In adenosis, all three markers, p63, p40 (DB), and p40 (CB), were expressed in the 
myoepithelial cells, and not in the luminal ducal cells (top panels). Most intraductal papillomas expressed p63 and 
p40 (DB) in the myoepithelial cells, but not in luminal ductal cells (middle panels). Most DCISs expressed p63, p40 
(DB), and p40 (CB) in the surrounding myoepithelial cells. p40 (CB) showed more frequent positivity in cancer cells 
of DCISs than the other two myoepithelial markers (bottom panels).
p40 in breast disease
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cases (27.8%); and p40 (CB) in 26 cases 
(72.2%). p40 (CB) had stronger expression in 
myoepithelial cells than in 
luminal ductal cells or in can-
cer cells (Figure 2, middle and 
bottom panels). 
Comparison of p63, p40 (DB), 
p40 (CB) expression profiles in 
myoepithelial cells according 
to the classification of breast 
disease
We performed a comparative, 
in-depth analysis of the expres-
sion profiles of myoepithelial 
markers in the various breast 
disease, based on the above 
immunohistochemical results. 
Table 3 presents the sensitivi-
ty, specificity, PPV, NPV, and 
accuracy for each myoepitheli-
al cell marker, according to 
breast disease: adenosis, intra- 
ductal papilloma, and DCIS. 
In adenosis, p63, p40 (DB), 
p40 (CB) expression profiles 
received 100% marks for all 
the categories. In intraductal 
Figure 2. Immunohistochemical expression of p63, p40 (DB), and p40 (CB) in IDC and metaplastic carcinoma. In 
IDCs, cancer cells showed more frequent nuclear positivity, with p40 (CB) exhibiting the greatest positivity, then p63 
and p40 (DB) (top panels). Squamous subtypes of metaplastic carcinomas showed positive activity for all the myo-
epithelial markers in the cancer cells (middle panels). Matrix-producing types showed positive activity exclusively 
for p40 (CB) (bottom panels).
Table 3. Sensitivity, Specificity, PPV, NPV, and Accuracy of p63, 
p40 (DB), and p40 (CB) in the Myoepithelial Cells According to 
Breast Disease
Category Adenosis Intraductal papilloma DCIS
Total (adenosis + intraductal 
papilloma + DCIS)
p63
    Sensitivity 100.0 91.2 90.3 93.8
    Specificity 100.0 100.0 96.8 99.0
    PPV 100.0 100.0 96.6 98.9
    NPV 100.0 91.9 90.9 94.1
    Accuracy 100.0 95.6 93.5 96.4
p40 (DB)
    Sensitivity 100.0 91.2 93.5 94.8
    Specificity 100.0 100.0 96.8 99.0
    PPV 100.0 100.0 96.7 98.9
    NPV 100.0 91.9 93.8 95.0
    Accuracy 100.0 95.6 95.2 96.9
p40 (CB)
    Sensitivity 100.0 100.0 96.8 99.0
    Specificity 100.0 97.1 71.0 85.8
    PPV 100.0 97.1 76.9 85.7
    NPV 100.0 100.0 95.7 99.0
    Accuracy 100.0 98.5 83.9 91.9
DCIS, ductal carcinoma in situ; PPV, positive predictive value; NPV, negative predic-
tive value.
papillomas, p63 and p40 (DB) showed 100% 
specificity and PPV, and p40 (CB) showed 100% 
p40 in breast disease
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sensitivity and received the highest accuracy 
(98.5%). In DCISs, p40 (CB) was the most sen-
sitive (96.8%), and p63 had the lowest sensitiv-
ity (90.3%). p40 (CB), however, received the 
lowest scores in the specificity and accuracy 
categories (71.0% and 83.9%, respectively). 
Accuracy was highest for p40 (DB) expression 
(95.2%).
p40 (CB) was the most sensitive (99.0%), but 
the least specific (85.8%), and p63 was the 
least sensitive (93.8%) in adenosis, IP, and 
DCIS. p40 (DB) ranked highest (96.9%) and 
p40 (CB) lowest (91.9%) in accuracy.
Clinicopathologic features of IDC according to 
the expression status of p63, p40 (DB), and 
p40 (CB)
Next, we investigated the correlation of the 
expression status of myoepithelial cell markers 
in cancer cells to the clinicopathologic features 
of IDC cases (Table 4). We classified 257 IDCs 
according to pathologic features (histologic 
grade, tumor size, lymph node metastasis, 
molecular subtype, predictive marker status 
[estrogen receptor, progesterone receptor, and 
HER-2], and proliferative index) and clinical fea-
tures (patient age, tumor recurrence, and sur- 
vival). 
As a result, p63 positivity in cancer cell compo-
nents was associated with higher histologic 
grade (P = 0.003), ER negativity (P = 0.021), 
triple negative type (P = 0.049), and higher 
Ki-67 LI (P = 0.028). This result is compatible 
with previous reports that p63 was more fre-
quently expressed in IDCs of triple negative 
type and basal-like type [3, 12]. p40 (DB) posi-
tivity in cancer cell component was associated 
with higher histologic grade (p = 0.022), ER 
negativity (P = 0.002), PR negativity (P = 0.006), 
Table 4. Clinicopathologic Features of Invasive Ductal Carcinoma, According to the Expression Status of 
p63, p40 (DB), and p40 (CB)
Parameters TotalN = 257
p63 p40 (DB) p40 (CB)
Negative
n = 249 (%)
Positive




n = 251 (%)
Positive




n = 226 (%)
Positive
n = 30 (%)
P- 
value
Age (years, mean ± SD) 51.2 ± 11.1 51.3 ± 11.2 47.8 ± 7.3 0.416 51.1 ± 11.1 57.6 ± 12.1 0.199 50.5 ± 10.9 56.2 ± 11.3 0.009
Histologic grade 0.003 0.022 0.106
    I 59 (23.0) 59 (23.6) 0 (0.0) 59 (23.4) 0 (0.0) 55 (24.2) 4 (13.3)
    II 122 (47.5) 121 (48.4) 1 (14.3) 121 (48.0) 1 (20.0) 108 (47.6) 14 (46.7)
    III 76 (29.6) 70 (28.0) 6 (85.7) 72 (28.6) 4 (80.0) 64 (28.2) 12 (40.0)
T stage 0.299 0.316 0.516
    1 162 (63.0) 158 (63.2) 4 (57.1) 160 (63.5) 2 (40.0) 145 (63.9) 17 (56.7)
    2 93 (36.2) 91 (36.4) 2 (28.6) 90 (35.7) 3 (60.0) 80 (35.2) 13 (43.3)
    3 2 (0.8) 1 (0.4) 1 (14.3) 2 (0.8) 0 (0.0) 2 (0.9) 0 (0.0)
Lymph node metastasis 0.704 0.657 0.420
    Absent 164 (64.1) 160 (64.3) 4 (57.1) 160 (63.7) 4 (80.0) 147 (65.0) 17 (56.7)
    Present 92 (35.9) 89 (35.7) 3 (42.9) 91 (36.3) 1 (20.0) 79 (35.0) 13 (43.3)
ER 0.021 0.002 0.029
    Negative 73 (28.4) 68 (27.2) 5 (71.4) 68 (27.0) 5 (100.0) 59 (26.0) 14 (46.7)
    Positive 184 (71.6) 182 (72.8) 2 (28.6) 184 (73.0) 0 (0.0) 168 (74.0) 16 (53.3)
PR 0.103 0.006 0.111
    Negative 94 (36.6) 89 (35.6) 5 (71.4) 89 (35.3) 5 (100.0) 79 (34.8) 15 (50.0)
    Positive 163 (63.4) 161 (64.4) 2 (28.6) 163 (64.7) 0 (0.0) 148 (65.2) 15 (50.0)
HER-2 1.000 0.587 0.639
    Negative 203 (79.0) 197 (78.8) 6 (85.7) 198 (78.6) 5 (100.0) 178 (78.4) 25 (83.3)
    Positive 54 (21.0) 53 (21.2) 1 (14.3) 54 (21.4) 0 (0.0) 49 (21.6) 5 (16.7)
Molecular subtype 0.049 < 0.001 0.021
    Luminal A 126 (49.0) 125 (50.0) 1 (14.3) 126 (50.0) 0 (0.0) 116 (51.1) 10 (33.3)
    Luminal B 63 (24.5) 62 (24.8) 1 (14.3) 63 (25.0) 0 (0.0) 56 (24.7) 7 (23.3)
    HER-2 18 (7.0) 17 (6.8) 1 (14.3) 18 (7.1) 0 (0.0) 17 (7.5) 1 (3.3)
    Triple negative 50 (19.7) 46 (18.4) 4 (57.1) 45 (17.9) 5 (100.0) 38 (16.7) 12 (40.0)
Ki-67 LI (%, mean ± SD) 15.6 ± 17.6 15.1 ± 17.1 30.0 ± 26.6 0.028 15.2 ± 17.3 35.0 ± 20.0 0.013 15.0 ± 17.3 20.0 ± 19.2 0.139
Tumor recurrence 12 (4.7) 11 (4.4) 1 (14.3) 0.287 12 (4.8) 0 (0.0) 1.000 11 (4.8) 1 (3.3) 1.000
Patient death 19 (7.4) 18 (7.2) 1 (14.3) 0.420 19 (7.5) 0 (0.0) 1.000 16 (7.0) 3 (10.0) 0.473
p40 in breast disease
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triple negative type (P < 0.001), and higher 
Ki-67 LI (P = 0.013). Lastly, p40 (CB) positivity 
in cancer cell components was associated with 
older age (P = 0.009), ER negativity (P = 0.029), 
and triple negative type (P = 0.021). To assess 
whether each myoepithelial cell marker had a 
different expression status, we performed 
Mann-Whitney tests (Figure 3A). The results 
indicate that p63 and p40 (DB) have a similar 
tendency to be expressed in cancer cells; how-
ever, p40 (CB) expression was statistically dif-
ferent from both p63 and p40 (DB).
Clinicopathologic features of metaplastic car-
cinoma according to the expression status of 
p63, p40 (DB), and p40 (CB)
Koker MM, et al. reported that p63 expression 
in breast cancer is highly sensitive and specific 
in metaplastic carcinoma [3]. Therefore, we 
examined whether there was any difference in 
the expression status between p63 and its iso-
form, p40, in metaplatic carcinomas. Table 5 
shows the comparison of clinicopathologic fea-
tures in 36 metaplastic carcinomas, according 
to the positivity of three myoepithelial markers. 
Interestingly, we found that p63 and p40 (DB) 
expression profiles were clearly distinct by his-
tologic subtype; they were highly expressed in 
squamous subtype but rarely expressed in 
matrix-producing and spindle subtypes (Figure 
2, middle and bottom panelss, P < 0.001). 
When we performed Mann-Whitney test with 
metaplastic cancers, the results indicated that 
p63 and p40 (DB) have similar expressions, 
however, p40 (CB) expression was statistically 
different from p63 and p40 (DB), much like the 
expression of IDCs (Figure 3B). 
Discussion
Tumor protein p63, a member of the p53 fami-
ly, has several isoforms. TAp63 and ΔNp63 
(p40) are known as the two major isoforms of 
p63. TAp63’s utility in the diagnosis of cancer 
has been reported in tumors for several organs. 
The diagnostic utility of p40, however, is still 
not well understood, particularly in breast dis-
ease. Thus, we examined diverse aspects of 
expression status of these two p63 isoforms in 
the cell components of breast disease ranging 
from benign proliferative lesions to malignant 
tumors. In order to verify their utility in diagnos-
ing breast disease, we used immunohisto-
chemical analysis to compare the expression 
profiles of p63 to p40, using pan-p63 antibody 
and p40 antibody, respectively. 
Previous studies reported that p63 is a highly 
sensitive myoepithelial marker, showing up in 
100% of expression profiles in normal myoepi-
thelial cells [1, 2]. We confirmed that p63 is 
very sensitive in detecting myoepithelial cells of 
benign proliferative lesions, such as adenosis 
Figure 3. Proportion of tumor cells expressing p63, p40 (DB), and p40 (CB). Among the three myoepithelial markers, 
p40 (CB) was the most frequently expressed in the cancer cells of IDC (A) and metaplastic carcinoma (B).
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and intraductal papilloma. Further, we found 
that p40 (DB) has the same expression in these 
cells as p63. Although p40 (CB) showed the 
greatest sensitivity among these three myoepi-
thelial markers in the two benign lesions and 
DCIS, it had the lowest specificity. It was 
expressed not only in the myoepithelial cells 
but also in the luminal ductal cells of adenosis 
and intraductal papilloma cases and in the 
tumor cells of DCIS, respectively. p40 (CB) 
expression was more frequently observed in 
tumor cells of DCIS than in luminal ductal cells 
of adenosis and intraductal papilloma. The 
expression intensity in tumor cells, however, 
was notably lower than that for myoepithelial 
cells. Therefore, we suggest that, in the practi-
cal diagnosis of DCIS, there is little chance for 
p40 (CB) to misdiagnose tumor cells as myoepi-
thelial cells. 
One of the drawbacks of using p63 is that it 
occasionally reveals positive activity in cancer 
cells of IDC [2, 3, 12, 13]. We also observed 
that p40 positivity and p63 positivity of cancer 
cells (2.7% of p63, 1.9% of p40 [DB], and 11.7% 
of p40 [CB]) in IDC was within the range of p63 
positive frequency, which had been reported in 
the previous studies. Interestingly, we discov-
ered that IDCs which show p63 and p40 (DB) 
activity in cancer cells, showed resemblances 
in the expression rate and clinicopathologic 
features between the two. IDCs with p40 (CB) 
activity, however, were significantly different to 
those with p63 and p40 (DB) activity, not only 
in expression rate, but also in clinicopathologic 
features. We were not sure whether the high 
sensitivity and lower specificity of p40 (CB) 
caused these differences, or whether p40 (CB) 
might be more detectable in cancer cells with 
myoepithelial differentiation. 
Next, we examined the expression status of 
myoepithelial cell markers in metaplastic carci-
noma, since p63 is known as a very sensitive 
Table 5. Clinicopathologic Features of Metaplastic Carcinoma, According to the Expression Status of p63, 
p40 (DB), and p40 (CB)
Parameters TotalN = 36
p63 p40 (DB) p40 (CB)
Negative
n = 27 (%)
Positive
n = 9 (%) P-value
Negative
n = 26 (%)
Positive
n = 10 (%) P-value
Negative
n = 11 (%)
Positive
n = 25 (%) P-value
Age (years, mean ± SD) 52.0 ± 10.1 51.3 ± 10.6 54.1 ± 8.5 0.478 51.4 ± 10.8 53.4 ± 8.3 0.614 50.5 ± 11.2 52.6 ± 9.7 0.575
Histologic grade 1.000 1.000 0.703
    II 11 (30.6) 8 (29.6) 3 (33.3) 8 (30.8) 3 (30.0) 4 (36.4) 7 (28.0)
    III 25 (69.4) 19 (70.4) 6 (66.7) 18 (69.2) 7 (70.0) 7 (63.6) 18 (72.0)
T stage 0.798 0.784 0.505
    1 11 (30.6) 8 (29.6) 3 (33.3) 8 (30.8) 3 (30.0) 5 (45.5) 6 (24.0)
    2 16 (44.4) 13 (48.1) 3 (33.3) 12 (46.2) 4 (40.0) 3 (27.3) 13 (52.0)
    3 9 (25.0) 6 (22.2) 3 (33.3) 6 (23.1) 3 (30.0) 3 (27.3) 6 (24.0)
Lymph node metastasis 0.648 1.000 0.678
    Absent 28 (77.8) 20 (74.1) 8 (88.9) 20 (76.9) 8 (80.0) 8 (72.7) 20 (80.0)
    Present 8 (22.2) 7 (25.6) 1 (11.1) 6 (23.1) 2 (20.0) 3 (27.3) 5 (20.0)
ER 1.000 1.000 0.216
    Negative 33 (91.7) 25 (92.6) 8 (88.9) 24 (92.3) 9 (90.0) 9 (81.8) 24 (96.0)
    Positive 3 (8.3) 2 (7.4) 1 (11.1) 2 (7.7) 1 (10.0) 2 (18.2) 1 (4.0)
PR 0.443 0.484 0.524
    Negative 34 (94.4) 26 (96.3) 8 (88.9) 25 (96.1) 9 (90.0) 10 (90.9) 24 (96.0)
    Positive 2 (5.6) 1 (3.7) 1 (11.1) 1 (3.8) 1 (10.0) 1 (9.1) 1 (4.0)
HER-2 1.000 1.000 0.306
    Negative (0, 1+) 35 (97.2) 26 (96.3) 9 (100.0) 25 (96.2) 10 (100.0) 10 (90.9) 25 (100.0)
    Equivocal (2+) 1 (2.8) 1 (3.7) 0 (0.0) 1 (3.8) 0 (0.0) 1 (9.1) 0 (0.0)
Histologic Subtype < 0.001 < 0.001 0.210
    Matrix-producing 23 (63.9) 22 (81.5) 1 (11.1) 21 (80.8) 2 (20.0) 9 (81.8) 14 (56.0)
    Rhabdoid 1 (2.8) 0 (0.0) 1 (11.1) 0 (0.0) 1 (10.0) 0 (0.0) 1 (4.0)
    Spindle 5 (13.9) 5 (18.5) 0 (0.0) 5 (19.2) 0 (0.0) 2 (18.2) 3 (12.0)
    Squamous 7 (19.4) 0 (0.0) 7 (77.8) 0 (0.0) 7 (70.0) 0 (0.0) 7 (28.0)
Ki-67 LI (%, mean ± SD) 42.5 ± 21.0 46.5 ± 21.0 31.1 ± 17.4 0.057 45.2 ± 20.2 36.0 ± 22.5 0.249 40.9 ± 16.8 43.3 ± 23.0 0.757
Distant metastasis 5 (13.9) 4 (14.8) 1 (11.1) 1.000 4 (15.4) 1 (10.0) 1.000 2 (18.2) 3 (12.0) 0.631
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and specific marker for this type of breast can-
cer, showing over 90% expression frequency 
[3]. In our study, however, the expression rate 
for each myoepithelial cell marker was much 
lower than previously reported. We believe that 
lower expression profiles of p63 in our study 
compared with the previous series could be 
explained by limitation of the TMA ability to 
accurately reflect data about large and heterog-
enous tumor specimens of metaplastic carci-
noma. When we histologically subdivided meta-
plastic carcinomas, according to the specific 
differentiations, both p63 and p40 (DB) expres-
sion status were different. Using these histo-
logic subtypes, most cases with squamous dif-
ferentiation showed positive activities; howev-
er, only minor cases with spindle cell differenti-
ation or matrix-producing type showed positive 
activity. Unlike p63 and p40 (DB), p40 (CB) 
showed high expression in metaplastic carcino-
mas, regardless of histologic subtype.
Thus we found that there are distinctions in 
expression profile between p40 (CB) and p40 
(DB) antibodies, which detect the same epitope 
of p63 protein. The difference is only that the 
former is monoclonal and the latter is poly-
clonal. The monoclonal antibody p40 (CB) had 
higher sensitivity and lower specificity than p40 
(DB), a polyclonal antibody, which differs from 
the common knowledge. Because we per-
formed the immunohistochemical assays under 
identical conditions, with the only variations in 
antibodies, we could not affirm why there were 
discrepancies in expression profiles among 
them. We considered p63 and p40 (DB) anti-
bodies to be virtually interchangeable in the 
diagnosis of breast disease, but, our results 
highlight that we should be careful in using p40 
(CB) positive cells for diagnosis, except when 
applied to myoepithelial cells. 
In summary, we investigated the expression 
patterns of pan-p63 and p40 antibodies in vari-
ous breast diseases, from benign proliferative 
diseases to malignant tumors, according to cel-
lular components, myoepithelial cells, and can-
cer cells. We tested the validity of these myo-
epithelial markers and found that p63 and p40 
(DB) expression status in myoepithelial cells 
were statistically similar in each other, while 
p40 (CB) positivity was more frequently 
observed in luminal cells, cancer cells, and 
myoepithelial cells. Therefore, we concluded 
that p40 antibodies as well as pan p63 anti-
body are very specific and sensitive myoepithe-
lial cell markers; however, p40 positivity in the 
cancer cell component should be interpreted 
carefully, considering its relatively lower 
specificity.
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